Research

Hormonal

54.6% of patients in the orforglipron 36-mg group achieved a weight reduction of 10% or more, compared to 12.9% in the placebo group.

A significant proportion of obese adults may achieve clinically meaningful weight loss with orforglipron.

StrongSupportsmedium confidence
Among the patients in the orforglipron 36-mg group, 54.6% had a reduction of 10% or more, as compared with 12.9% of the patients in the placebo group.
Sean Wharton et al. · New England Journal of Medicine · 2025

Why this rating

Based on a phase 3 randomized controlled trial design.

Source

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment

Sean Wharton et al. · New England Journal of Medicine · 2025

DOI 10.1056/nejmoa2511774

rct · n=3127Cited 69×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →